Liposomal formulations of finasteride and minoxidil may enhance drugdelivery to the skin and hairfollicles more effectively than traditional solutions, potentially improving treatment outcomes. However, more human clinical trials are needed to confirm these benefits.
A gel of keratin microspheres promotes hairfollicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drugdelivery for hair-related disorders.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.
The conversation discusses the idea of creating finasteride gummies for hair loss treatment, with some users expressing skepticism about their effectiveness compared to pills. Concerns include the potential for reduced drugdelivery in gummy form and the risk of children mistaking them for candy.
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hairfollicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.